« Back to Vicor Press Releases
Contact:
David H. Fater
President and Chief Executive Officer
(800) 998-9964
Daniel N. Weiss, M.D., F.A.C.C. Joins Scientific Advisory Board
BOCA RATON, FLORIDA — September 22, 2003 — VICOR TECHNOLOGIES, INC. ("Vicor" or "the Company") today announced Daniel N. Weiss, M.D., F.A.C.C. has joined Vicor's Scientific Advisory Board and has become a consultant to the Company.
Daniel N. Weiss, M.D., F.A.C.C., a member of Florida Arrhythmia Consultants since 1994, is a clinical electrophysiologist. He also serves as a consultant to Fortune 500 Medical Device companies including Guidant, St. Jude and Medtronics. He has been an investigator for both the MADIT II (MultiCenter Automatic Defibrillator Implantation Trial) and SCDHeFT (Sudden Cardiac Death Heart Failure Trial). Dr. Weiss is a cum laude graduate of Princeton University with a BSE in Electrical Engineering and Computer Science. He received his Medical Degree with Distinction in Research from the Mount Sinai School of Medicine where he also received the Nathan A. Setz Award for Research in Cardiovascular and Renal Disease.
Commenting on the relationship, David H. Fater, President and Chief Executive Officer of Vicor said "We are extremely pleased and delighted to have a clinical physician with Dr. Weiss's background and credentials join our Scientific Advisory Board and become a consultant to the Company. His clinical knowledge and physician perspective are important as we transition from a development company to a commercial company once FDA clearance for our PD2i Cardiac Analyzer is received and the marketing is launched."
Vicor Technologies, Inc. is a biotechnology company dedicated to the development of breakthrough diagnostic and therapeutic products. The Company's diagnostics products are based on the Company's patented PD2i algorithm, which is used to predict future pathological events, specifically but not limited to, fatal cardiac arrhythmic death, Mad Cow Disease, and a number of other high profile diagnostic indications. Vicor's therapeutic products have been developed by using an innovative drug discovery platform which focuses on naturally occurring biomolecules derived from state-dependent physiologies such as hibernation.
Certain statements contained herein are "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
Vicor Technologies, Inc., prepared this update and is solely responsible for its content.